Arcturus Therapeutics Holdings Gross Profit

The latest gross profit for ARCT is $46M as of June 2026. That compares with $91M in the prior-year period — down 49.4% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Arcturus Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, ARCT's gross profit moved from $91M to $46M — a 49.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Arcturus Therapeutics Holdings's operating scale or balance-sheet position.

Against Healthcare companies, ARCT currently prints $46M for gross profit, while the sector average sits near $66B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Arcturus Therapeutics Holdings's growth, margins, and balance sheet.

A gross profit figure of $46M for ARCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting ARCT's gross profit ($46M), review year-over-year change from $91M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.